- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05975073
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
May 2, 2024 updated by: Amgen
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
184
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
South Australia
-
Woodville South, South Australia, Australia, 5011
- Recruiting
- The Queen Elizabeth Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Medical Centre
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope National Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46250
- Recruiting
- Community Health Network MD Anderson Cancer Center - North
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Recruiting
- Astera Cancer Care
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Recruiting
- Prisma Health Upstate
-
-
Texas
-
Irving, Texas, United States, 75039
- Recruiting
- Next Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Evidence of homozygous loss of MTAP (null) and/or MTAP deletion.
Presence of advanced/metastatic solid tumor not amenable to curative treatment
- Part 1: MTAP-null or lost MTAP expression solid tumor for which no standard therapy exists
- Part 2: MTAP-null or lost MTAP expression NSCLC with progression after 1 to 2 prior lines of systemic therapy.
- Able to swallow and retain PO administered study treatment and willing to record adherence to investigational product
- Disease measurable as defined by RECIST v1.1
- Adequate organ function as defined in the protocol.
- Archived tumor tissue. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before cycle 1 day 1 dosing.
Exclusion Criteria
- Prior treatment with an MAT2A inhibitor or a PRMT5 inhibitor.
- Radiologic or clinical evidence of spinal cord compression, untreated or symptomatic brain metastases or leptomeningeal disease.
- Cardiovascular and pulmonary exclusion criteria as defined in the protocol.
- Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis)
- History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study entry.
- Prior irradiation to > 25% of the bone marrow
- Use of prescription medications that are known strong CYP3A4/5 inducers or strong CYP3A4/5 inhibitors within 7 days for CYP3A4/5 inhibitors, 14 days for CYP3A4/5 inducers or 5 half-lives, whichever is longer, prior to any dose of investigational medical product.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Dose Exploration of AMG 193 Combined With IDE397
Participants will receive escalating doses of AMG 193 and IDE397 administered orally (PO) in cycles of 21 days.
|
Administered PO
Administered PO
|
Experimental: Part 2: Dose Expansion of AMG 193 Combined With IDE397
AMG 193 and IDE397 will be administered PO in cycles of 21 days.
|
Administered PO
Administered PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
Time Frame: Day 1 up to Day 21
|
Day 1 up to Day 21
|
|
Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time Frame: Day 1 up to approximately 2.5 years
|
Any clinically significant changes in vital signs, electrocardiogram (ECG), or clinical laboratory test results will be recorded as adverse events
|
Day 1 up to approximately 2.5 years
|
Part 1: Number of Participants Experiencing Serious Adverse Events (SAEs)
Time Frame: Day 1 up to approximately 2.5 years
|
Day 1 up to approximately 2.5 years
|
|
Part 2: Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time Frame: Day 1 up to approximately 2.5 years
|
Day 1 up to approximately 2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 and 2: Maximal Plasma Concentration (Cmax) of AMG 193
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Part 1 and 2: Cmax of IDE397
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Part 1 and 2: Time to Achieve Maximal Plasma Concentration (Tmax) of AMG 193
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Part 1 and 2: Tmax of IDE397
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Parts 1 and 2: Area Under The Curve (AUC) After Single Dose of AMG 193
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Parts 1 and 2: Area Under The Curve (AUC) After Multiple Doses of AMG 193
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Parts 1 and 2: AUC After Single Dose of IDE397
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Parts 1 and 2: AUC After Multiple Doses of IDE397
Time Frame: Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
Day 1 pre-dose up to Cycle 5 (Cycle= 21 days)
|
|
Parts 1: Overall Response per RECIST 1.1
Time Frame: Day 1 up to end-of-study (EOS) (approximately 2.5 years)
|
Day 1 up to end-of-study (EOS) (approximately 2.5 years)
|
|
Parts 1 and 2: Disease Control Rate
Time Frame: Day 1 up to EOS (approximately 2.5 years)
|
Day 1 up to EOS (approximately 2.5 years)
|
|
Parts 1 and 2: Time to Response (TTR)
Time Frame: Day 1 up to EOS (approximately 2.5 years)
|
Day 1 up to EOS (approximately 2.5 years)
|
|
Parts 1 and 2: Duration of Response (DOR)
Time Frame: Day 1 up to EOS (approximately 2.5 years)
|
Day 1 up to EOS (approximately 2.5 years)
|
|
Parts 1 and 2: Duration of Stable Disease
Time Frame: Day 1 up to EOT (approximately 6 months)
|
Day 1 up to EOT (approximately 6 months)
|
|
Parts 1 and 2: Progression-free Survival (PFS)
Time Frame: Day 1 up to EOS (approximately 2.5 years)
|
Day 1 up to EOS (approximately 2.5 years)
|
|
Parts 1 and 2: Overall Survival (OS)
Time Frame: Day 1 up to EOS (approximately 2.5 years)
|
Day 1 up to EOS (approximately 2.5 years)
|
|
Part 2: Number of Participants Experiencing TEAEs
Time Frame: Day 1 up to approximately 2.5 years
|
Any clinically significant changes in vital signs, electrocardiogram (ECG), or clinical laboratory test results will be recorded as adverse events
|
Day 1 up to approximately 2.5 years
|
Part 2: Number of Participants Experiencing SAEs
Time Frame: Day 1 up to approximately 2.5 years
|
Day 1 up to approximately 2.5 years
|
|
Parts 1 and 2: Change From Baseline in Symmetric Dimethylation of Arginine (SDMA) in Blood
Time Frame: Baseline (Day 1) to EOT plus 30 days (approximately 7 months)
|
Baseline (Day 1) to EOT plus 30 days (approximately 7 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2023
Primary Completion (Estimated)
December 27, 2025
Study Completion (Estimated)
July 20, 2026
Study Registration Dates
First Submitted
July 19, 2023
First Submitted That Met QC Criteria
July 27, 2023
First Posted (Actual)
August 3, 2023
Study Record Updates
Last Update Posted (Actual)
May 6, 2024
Last Update Submitted That Met QC Criteria
May 2, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20220127
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD Sharing Time Frame
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities.
There is no end date for eligibility to submit a data sharing request for this study.
IPD Sharing Access Criteria
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s).
In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling.
Requests are reviewed by a committee of internal advisors.
If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision.
Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.
This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications.
Further details are available at the URL below.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MTAP-null Non-Small-Cell Lung Cancer
-
AmgenRecruitingAdvanced MTAP-null Solid TumorsUnited States, Canada, Taiwan, Switzerland, United Kingdom, Korea, Republic of, Germany, Austria, France, Belgium, Australia, Hong Kong, Japan
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on AMG 193
-
AmgenRecruitingAdvanced MTAP-null Solid TumorsUnited States, Canada, Taiwan, Switzerland, United Kingdom, Korea, Republic of, Germany, Austria, France, Belgium, Australia, Hong Kong, Japan
-
Ludwig Institute for Cancer ResearchWyeth is now a wholly owned subsidiary of PfizerTerminated
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada
-
Southwest Oncology GroupNational Cancer Institute (NCI)RecruitingLung Adenocarcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States, Guam
-
AmgenCompleted
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada